Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy

Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy

The elevation of SMN transcript and protein level remains the principal aim of SMA therapy. Still, there is no standard molecular biomarker for the assessment of its efficacy. In the current study, we tested three methods of SMN transcript level measurement using real-time RT-PCR, quantitative fluor...

Full description

Bibliographic Details
Main Authors: Marianna Maretina, Anna Egorova, Kristina Lanko, Vladislav Baranov, Anton Kiselev
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Genes
Subjects:
spinal muscular atrophy
SMN transcripts
molecular biomarker
antisense oligonucleotides
SMN expression
<i>SMN2</i> gene
Online Access:https://www.mdpi.com/2073-4425/13/10/1911

Internet

https://www.mdpi.com/2073-4425/13/10/1911

Similar Items